Pharmacyclics, Inc. (NASDAQ:PCYC), was upgraded by equities research analysts at Ned Davis Research from a “sell” rating to a “neutral” rating in a research note issued to investors on Monday, AnalystRatings.NET reports. Pharmacyclics, Inc. (NASDAQ:PCYC), shares after opening at $94.85 moved to $94.85 on last trade day and at the end of the day closed at $88.70. Company price to sales ratio in past twelve months was calculated as 25.57 and price to cash ratio as 10.47. Pharmacyclics, Inc. (NASDAQ:PCYC), showed a negative weekly performance of 1.17%.
On April 22, 2014, Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it will host an investor event and a live webcast on Tuesday, April 29, 2014 at 6:00 p.m. Eastern Time to discuss the ISIS-SMNRx data presented at the 2014 American Academy of Neurology Annual Meeting. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), shares fell 6.99% in last trading session and ended the day on $32.74. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), return on equity ratio is recorded as -18.10% and its return on assets is -8.10%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), yearly performance is 45.90%.
On April 9, 2014, Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) announces issue of ordinary shares to carry out its business proceeds. The firm has decided to issue 59.17 million ordinary shares for a consideration of a $16.38 million. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), shares moved down 6.00% in last trading session and was closed at $1.88, while trading in range of $ 1.86 – 2.01. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), year to date (YTD) performance is -73.18%.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Tuesday, Stock Ratings News reports. They currently have a $53.00 target price on the stock. Zacks‘s price target would suggest a potential upside of 4.60% from the stock’s previous close. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), weekly performance is -4.25%. On last trading day company shares ended up $48.69. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), distance from 50-day simple moving average (SMA50) is -1.66%. Analysts mean target Price for the company is $55.36.
Leave a Reply